You just read:

Esperance Pharmaceuticals Initiates Phase 2 Clinical Trial of its Novel Membrane-disrupting Agent, EP-100, in Patients with Advanced Ovarian Cancer

News provided by

Esperance Pharmaceuticals

May 17, 2012, 01:57 ET